Q-omics provides the consensus-scored LCK profile across patient tissues and cancer cell-line models. LCK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LCK is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LCK RNA expression shows 18,005 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KIRC, and LSCC as cancer lineages where LCK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCK survival associations across molecular data types. LCK RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCK RNA expression–survival associations across cancer types. High LCK expression shows unfavorable associations in UVM, but favorable associations in UCEC, HNSC, SKCM, CESC and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LCK RNA expression.
This table summarizes LCK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LCK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCK shows lower tumor expression in KICH and higher tumor expression in KIRC, STAD, ESCA, HNSC and THCA. The KIRC box plot shows higher LCK RNA expression in tumor versus normal tissue (log2 FC = +1.574, t-test p < 0.001).
This table shows molecular features associated with LCK in patient tissues and cancer cell lines. In patient samples, LCK shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LCK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
